trending Market Intelligence /marketintelligence/en/news-insights/trending/pidHEjDLlFp7eukZ-gX-4Q2 content esgSubNav
In This List

India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Pfizer Ltd. agreed to acquire the Neksium brand in India from AstraZeneca PLC's Swedish unit AstraZeneca AB for 750 million Indian rupees.

India-based Pfizer said the acquisition of the brand will complement its existing product portfolio in the gastrointestinal therapeutic area.

The closing of the transaction is subject to customary closing conditions.